Our new report presents findings from services responsible for conducting child protection medical assessments. It shows positive national results in many areas, but a need to better protect our safeguarding workforce.
Dr Emily Parker is one of our new Clinical Fellows with the Clean Air Fund Partnership, and in her first blog, she describes how doctors are taking a more critical look at the impact of air pollution on children's health.
We hope you can join us on 25-27 March for our major event. With the input of more than 35 specialty groups, inspiring speakers and practical workshops, you can update your knowledge on what matters to you.
The Neonatal and Paediatric Pharmacy Group (NPPG), with support from the Royal College of Paediatrics of Child Health (RCPCH) has produced a proposal for a national approach for standardised intravenous infusion concentrations in children.
Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019 due to the presence of low levels of an impurity called NDMA. The European Medicines Agency has since confirmed its recommendation to suspend all ranitidine medicines in the EU.
We are very pleased to announce the publication of this latest position statement produced by the Neonatal and Paediatric Pharmacy Group (NPPG) and endorsed by the Royal College of Paediatrics and Child Health (RCPCH) regarding how to choose an oral liquid for a child.
The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.
Last week, NICE published draft recommendations on the use of cannabis-based medicinal products (CBMPs) following evaluation of their clinical and cost-effectiveness, and NHS England published a review aimed at assessing the barriers to prescribing cannabis-based medicinal products where it is safe ...